Comment on: Characterization of the embB gene in Mycobacterium tuberculosis isolates from Barcelona and rapid detection of main mutations related to ethambutol resistance using a low-density DNA array by Köser, Claudio U. et al.
J Antimicrob Chemother 2014; 69: 2298–2303
doi:10.1093/jac/dku101
Advance Access publication 20 April 2014
Comment on: Characterization
of the embB gene in
Mycobacterium tuberculosis isolates
from Barcelona and rapid detection
of main mutations related to
ethambutol resistance using a
low-density DNA array
Claudio U. Ko¨ser1*†, Josephine M. Bryant2†,
In˜aki Comas3,4†, Silke Feuerriegel5,6, Stefan Niemann5,6,
Sebastien Gagneux7,8, Julian Parkhill2 and
Sharon J. Peacock1,2,9,10
1Department of Medicine, University of Cambridge, Cambridge, UK;
2Wellcome Trust Sanger Institute, Hinxton, UK; 3Genomics and
Health Unit, FISABIO, Valencia, Spain; 4CIBER (Centros de
Investigacio´n Biome´dica en Red) in Epidemiology and Public Health,
Barcelona, Spain; 5Molecular Mycobacteriology, Borstel, Germany;
6German Centre for Infection Research, Research Centre Borstel,
Borstel, Germany; 7Department of Medical Parasitology and
Infection Biology, Swiss Tropical and Public Health Institute, Basel,
Switzerland; 8University of Basel, Basel, Switzerland; 9Clinical
Microbiology and Public Health Laboratory, Public Health England,
Cambridge, UK; 10Cambridge University Hospitals NHS Foundation
Trust, Cambridge, UK
*Corresponding author. Tel: +44-1223-331664; Fax: +44-1223-336846;
E-mail: cuk21@cam.ac.uk
†Contributed equally.
Keywords: Mycobacterium tuberculosis complex, phylogenetic
diversity, ethambutol resistance
Sir,
We agree with Moure et al.1 that fast genotypic methods will play
an increasingly prominent role in drug susceptibility testing for
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Figure 1. Whole-genome phylogeny of 219 isolates representative of all major MTBC lineages.9 Glu at codon 378 is a marker for modern MTBC, which all
share the TbD1 deletion and include the lineage 4 M. tuberculosis H37Rv laboratory strain that is used as the reference/wild-type sequence for sequence
analyses.10
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the Mycobacterium tuberculosis complex (MTBC).2,3 We would,
however, like to point out that the embB (Rv3795) Glu378Ala
polymorphism, which is detected by probe 3 of their newly
developed low-density DNA array, is not a marker for ethambutol
resistance.4 – 7 Instead, Ala represents the ancestral amino acid at
this codon (Figure 1), whereas Glu is present in all modern MTBC
(lineages 2, 3 and 4).6 – 9 The MIRU–VNTR data of the 51
ethambutol-resistant isolates from the study by Moure et al.1
are largely congruent with this finding. All 49 phylogenetically
modern MTBC isolates had the embB 378 Glu variant. Isolate
5765 was a representative of Mycobacterium bovis, which is
consistent with the fact that it harboured the Ala variant and
was pyrazinamide resistant. By contrast, it was unclear why
isolate 233R, which appeared to be M. bovis based on its MIRU–
VNTR signature, had the Glu variant (experimental error or a
homoplastic event might account for this discrepancy).
In light of these data, the results of probe 3 would be predicted
to lead to systematic false-positive reports, which calls into ques-
tion the validity of this probe. This underlines that the entire MTBC
diversity has to be considered when designing and validating
genotypic drug susceptibility testing assays.7,10
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